Long-acting cabotegravir PrEP: a time for cautious optimism

Lancet HIV. 2023 Dec;10(12):e756-e757. doi: 10.1016/S2352-3018(23)00294-1. Epub 2023 Nov 9.

Authors

David Wj Griffin¹, Jennifer F Hoy², James H McMahon³

Affiliations

¹ Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, VIC, Australia. Electronic address: d.griffin@alfred.org.au.
² Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, VIC, Australia.
³ Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, VIC, Australia; Department of Infectious Diseases, Monash Health, Melbourne, VIC, Australia.

PMID: 37952552
DOI: 10.1016/S2352-3018(23)00294-1

No abstract available

Publication types

Comment

MeSH terms

Anti-HIV Agents* / therapeutic use
HIV Infections* / drug therapy
HIV Infections* / prevention & control
Humans
Pre-Exposure Prophylaxis*
Pyridones / therapeutic use

Substances

cabotegravir
Anti-HIV Agents
Pyridones